This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Epidermolysis bullosa dystrophica디스트로피성 수포성 표피박리증

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q81.2 / Special Copayment Reduction: V184 / Re-approval cycle: 5 years
B. SynonymsNone
C. Adult onsetOnset at birth or in infancy; the mild form (dominant form) allows survival into adulthood with persistent skin symptoms; the severe recessive form carries a high risk of skin cancer
1. HistoryDystrophic EB first described in the 19th century; COL7A1 mutations identified in 1986, anchoring fibril defect confirmed
2. CausesDeficiency or abnormality of type VII collagen due to COL7A1 gene mutations → impaired anchoring fibril formation
3. GeneticsBoth the dominant form (DDEB: AD) and the recessive form (RDEB: AR) are due to COL7A1 (3p21.3) mutations
4. General epidemiologyDystrophic type is about 25% of all EB; incidence about 2~3/1,000,000 births; RDEB-generalized severe has the highest severity
5. PathophysiologyType VII collagen abnormality → loss of anchoring fibrils → separation below the lamina densa (sub-lamina densa) → blistering and scarring
6. SymptomsSkin blisters, erosions, and scarring, pseudosyndactyly, esophageal stricture, mucosal involvement, anemia, high risk of skin cancer (SCC)
7. SignsScarring blisters, milia, pseudosyndactyly of fingers and toes, nail dystrophy, signs of esophageal stricture
8. ScreeningFamily history-based prenatal genetic testing; immunofluorescence mapping (type VII collagen antibody)
9. DiagnosisTEM (loss/reduction of anchoring fibrils) + immunofluorescence (type VII collagen) + COL7A1 molecular genetic testing
10. TreatmentWound care, nutritional support, esophageal dilation, skin cancer surveillance, beremagene geperpavec gene therapy
11. PrognosisDDEB: normal lifespan possible; severe RDEB: mean survival 25~35 years, squamous cell carcinoma the main cause of death
12. PreventionGenetic counseling, prenatal diagnosis, PGD; UV protection and regular surveillance to prevent skin cancer
13. ReferencesFine JD et al. (2014) Inherited epidermolysis bullosa: updated recommendations and 9 other papers

1. History

Epidermolysis bullosa dystrophica (EBD) is the dystrophic type of epidermolysis bullosa (EB), divided by mode of inheritance into dominant (dominant dystrophic EB, DDEB) and recessive (recessive dystrophic EB, RDEB) forms. The name "dystrophic" derives from the characteristic dystrophic changes that appear after skin blistering, such as scarring, milia formation, and pseudosyndactyly of the fingers and toes.

Early descriptions of epidermolysis bullosa date from the mid-19th century, and Köbner (1886) first systematically described the clinical features of hereditary epidermolysis bullosa. Subsequently, Hallopeau (1896), Touraine (1942), and others distinguished the clinical differences between the dominant and recessive forms, and with the introduction of electron microscopy in the mid-20th century, it was shown that the site of blister formation in dystrophic EB is below the lamina densa (sub-lamina densa).

The decisive elucidation of the molecular pathogenesis came in 1986, when Leigh et al. reported that abnormalities of type VII collagen (collagen VII) are associated with anchoring fibril defects. Subsequently, the COL7A1 gene was cloned in 1992, and in 1993~1994 research groups including Christiano and Uitto confirmed that COL7A1 mutations are the cause of both dominant and recessive dystrophic EB. COL7A1 is cited as a classic example in the genetics of hereditary skin diseases because mutations in a single gene produce highly diverse phenotypes depending on mode of inheritance (autosomal dominant vs. recessive) and clinical severity.

Since the 2000s, research on EB gene therapy has advanced rapidly, and in 2023 the US FDA approved beremagene geperpavec (Vyjuvek) as the first topical gene therapy for dystrophic EB, establishing a milestone in the history of treatment. This therapy carries the COL7A1 gene in an HSV-1-based vector and is applied topically to wound sites, and clinical trials confirmed that it significantly reduces the frequency of blister formation.

2. Causes

The cause of epidermolysis bullosa dystrophica is deficiency or structural abnormality of type VII collagen (collagen type VII) due to COL7A1 gene mutations. Type VII collagen is the main component of the anchoring fibrils located below the lamina densa of the epidermal basement membrane, and it mechanically anchors the epidermal basement membrane to the underlying dermal collagen structures.

Type VII collagen is a homotrimer protein composed of three identical α1(VII) chains, and each chain consists of an N-terminal noncollagenous domain (NC-1), a central triple helix collagen domain, and a C-terminal noncollagenous domain (NC-2). The NC-1 domain binds laminin-332, fibronectin, etc. to anchor to the basement membrane, and the NC-2 domain forms an antiparallel dimer structure, creating the unique structure of the anchoring fibrils.

The clinical phenotype is determined by the type and location of COL7A1 mutations. In dominant dystrophic EB (DDEB), glycine substitution mutations in the triple helix domain are mainly observed. When a glycine (the Gly of the Gly-X-Y repeat sequence) is substituted by another amino acid, triple helix formation is disrupted and altered type VII collagen is produced. This abnormal protein forms trimers with the normal protein (dominant-negative effect), reducing overall anchoring fibril function.

In recessive dystrophic EB (RDEB), mainly nonsense, frameshift, and splice-site mutations are present on both alleles, so type VII collagen expression is severely reduced or completely lost. In the severe recessive form (RDEB-generalized severe), type VII collagen is not expressed at all or only trace amounts are detected. In the intermediate recessive form (RDEB-generalized intermediate), partial expression often remains.

3. Genetics

Epidermolysis bullosa dystrophica is caused by mutations in the single gene COL7A1 and is divided by mode of inheritance into the dominant form (DDEB: autosomal dominant, AD) and the recessive form (RDEB: autosomal recessive, AR). COL7A1 is located on chromosome 3p21.3, consists of 118 exons, and encodes an mRNA of about 9.2 kb. It has the largest and most complex structure among human collagen genes.

To date, more than 600 pathogenic COL7A1 variants have been reported (per HGMD), and a unique mutation is often found in each family (private mutation). However, some recurrent mutations also exist. In the dominant form, glycine substitution is the main mutation type, and among these, p.Gly2043Arg, p.Gly1991Ser, etc. have been reported in many pedigrees. In the recessive form, truncating mutations such as c.6527insC and p.Arg2814X are frequent.

Genotype-phenotype correlation is important. In general, the dominant form shows an intermediate phenotype through glycine substitution in the triple helix → dominant-negative effect, while the severe recessive form shows the most severe clinical picture through homozygous truncating mutations → complete loss of type VII collagen. The intermediate recessive form is when compound heterozygous truncating + missense or homozygous missense mutations leave partial protein expression.

Children of patients with the dominant form have a 50% chance of being affected, and children of the parents (each a carrier) of patients with the recessive form have a 25% chance. Rarely, revertant mosaicism is observed in patients with the recessive form; this is a phenomenon in which cell clones exist whose normal COL7A1 function has been partially restored by a second mutation or gene crossover at the somatic level, and it is being studied as a therapeutic model.

4. General epidemiology

The incidence of all epidermolysis bullosa is reported as about 19~50/1,000,000 births, and among these, dystrophic EB (DEB) has a frequency of about 2~3/1,000,000 births. The dystrophic type accounts for about 25% of all EB. According to US NEBR data, the prevalence of DEB is about 6/1,000,000 people.

The relative frequencies of the dominant and recessive forms vary by region and population, but because the dominant form is generally clinically less severe than the mild to intermediate recessive forms, it may account for a larger proportion of prevalence. The severe recessive form (RDEB-generalized severe, formerly the Hallopeau-Siemens type) is clinically the most severe of all EB subtypes, and the incidence of this subtype is about 1~2/1,000,000 births.

There is no sex bias in either the dominant or the recessive form. The frequency of the recessive form is high in populations where consanguineous marriage is common. Epidemiologic data for East Asian populations, including Korea, are limited, but the disease is distributed worldwide. In Korea, partial assessment is possible through rare disease Special Copayment Reduction registration statistics (Health Insurance Review & Assessment Service (HIRA)), but accurate nationwide prevalence data are lacking.

In patients with severe RDEB, the development of cutaneous squamous cell carcinoma (SCC) is a serious epidemiologic problem. The risk of SCC increases significantly from the 20s, and there are reports that the cumulative incidence of SCC reaches more than 90% by age 55. SCC is currently the main cause of death in RDEB patients.

5. Pathophysiology

The core of the pathophysiology of epidermolysis bullosa dystrophica is loss or dysfunction of anchoring fibrils due to type VII collagen abnormality. At the normal dermal-epidermal junction (DEJ), anchoring fibrils are unique structures that originate from the underside of the basement membrane lamina densa and connect to anchoring plaques and collagen fibers in the dermis. By mechanically anchoring the epidermis to the dermis, these anchoring fibrils provide resistance to external forces.

When type VII collagen is deficient or structurally abnormal, anchoring fibrils are reduced or lost, and the epidermis readily separates from the dermis at the level below the lamina densa (sub-lamina densa). Blisters form at this fragile junction even with mild mechanical stimulation, and this is the basic pathophysiology of dystrophic EB.

In the healing process after blister formation, scarring characteristically occurs. Unlike EB simplex, in the dystrophic type the repeated blister-erosion-healing cycle leaves dermal fibrosis and scars, which cause pseudosyndactyly of the fingers and toes, esophageal stricture, muscle contractures, etc. Especially in severe RDEB, as blister formation, healing, and scarring repeat, the fingers progress to pseudosyndactyly (mitten deformity), in which the fingers become bound together by thick scar tissue.

The high incidence of skin cancer (SCC) observed in severe RDEB is understood to result from the combined action of chronic inflammation, repeated wound healing, accumulation of DNA damage, and immune dysfunction. Some studies suggest that type VII collagen itself may have a tumor-suppressive role, and a mechanism by which its deficiency directly contributes to accelerated SCC development has been proposed.

6. Symptoms

The severity of the clinical symptoms of epidermolysis bullosa dystrophica differs greatly between the dominant and recessive forms, and all appear at birth or in early infancy. Skin blisters are the most basic symptom, occurring with mild friction or pressure, and appearing even spontaneously in the severe recessive form. After blister rupture, erosion, secondary infection, and scarring progress sequentially.

In the severe recessive form (RDEB-generalized severe), the repeated blister-scar cycle progresses, resulting in pseudosyndactyly of the fingers and toes (pseudosyndactyly, mitten deformity), which makes fine hand movements such as holding a spoon and chopsticks or writing impossible. Flexion contractures of the joints of the limbs also progress.

Gastrointestinal involvement is prominent. Difficulty chewing and swallowing due to oral blisters, erosions, and tongue adhesion, and esophageal stricture due to blisters and scarring of the esophageal mucosa occur, severely limiting food intake. Weight loss, growth retardation, and chronic malnutrition are common. In some cases, anal stricture also occurs.

Chronic anemia results from a combination of chronic inflammation, chronic blood loss, impaired iron absorption, etc., and is difficult to treat. Cutaneous squamous cell carcinoma (SCC) is the most lethal long-term complication of severe RDEB. It begins to occur from the 10s~20s, tends to grow and metastasize rapidly, and shows much more aggressive biological behavior than SCC in the general population. In addition, systemic complications such as kidney disease (IgA nephropathy, etc.), dilated cardiomyopathy, and osteoporosis are also reported.

7. Signs

The most characteristic finding on physical examination is scar formation after skin blisters. Blisters arise beneath the epidermis, are clear or hemorrhagic, and tense or flaccid. After healing, atrophic scars and milia remain. Milia are keratin cysts formed when epidermal appendages are trapped within scar tissue during blister healing, and they are a very characteristic finding of dystrophic EB.

In the severe recessive form, pseudosyndactyly of the fingers and toes progresses, deforming the hands into a glove or mitten shape. This is not simple skin adhesion but a state of being encased in fibrous tissue. Nail dystrophy or complete loss of nails (anonychia) is also common.

In the oral cavity, tongue adhesion, enamel hypoplasia, and restricted mouth opening (microstomia) are observed. Multiple dental caries and early tooth loss due to enamel dysplasia are also characteristic findings. Ophthalmologically, conjunctivitis, corneal erosions, and rarely corneal opacity are observed. Growth retardation, delayed puberty, and general frailty affect physical development.

Skin cancer tends to develop at sites of repeated blistering and erosion, such as the distal limbs, back, and abdomen, and SCC should be suspected when an ulcerative or hyperkeratotic lesion newly appears or an existing wound does not improve. When lymphadenopathy is present, the possibility of metastasis must be ruled out.

8. Screening

Screening for epidermolysis bullosa dystrophica is carried out mainly through family history-based prenatal diagnosis and diagnostic screening based on clinical suspicion. When there is a family history (previous birth of an affected child, or a family with an identified carrier/patient), prenatal molecular genetic testing is planned for pregnancy.

Immunofluorescence mapping evaluates the level of type VII collagen expression in the basement membrane in skin biopsies using type VII collagen-specific antibodies (LH7.2, etc.). In the severe recessive form, type VII collagen immunofluorescence is markedly reduced or absent, while in the dominant form reduced or normal levels may be observed. This is useful for subtype classification before molecular genetic testing.

For prenatal screening, COL7A1 molecular genetic testing is performed after CVS (first trimester) or amniocentesis (second trimester). Targeted testing is possible provided the familial mutation has been identified; if not, EB gene panel NGS testing is applied. Preimplantation genetic diagnosis (PGD) is also offered as an option. A newborn screening (NBS) program is currently not in place.

In patients already diagnosed with severe RDEB, skin cancer screening is essential. Regular full-body skin examinations (recommended at 6~12-month intervals), biopsy of suspicious lesions, and imaging studies (metastasis evaluation) are carried out systematically. Multiorgan follow-up screening, such as regular dental checkups, regular ophthalmologic examinations, and esophageal endoscopy (stricture surveillance), is also recommended.

9. Diagnosis

The diagnosis of epidermolysis bullosa dystrophica is confirmed by a three-step approach of clinical findings + skin biopsy (TEM + immunofluorescence) + COL7A1 molecular genetic testing.

On transmission electron microscopy (TEM), the characteristic finding of dystrophic EB is a reduction or absence of anchoring fibrils. In the severe recessive form, anchoring fibrils are not seen at all or are observed only very rarely, and the site of blister separation is below the lamina densa (sub-lamina densa). In the dominant form and the mild recessive form, anchoring fibrils are reduced and morphologic abnormalities (structural irregularity, short forms, etc.) are observed.

In immunofluorescence mapping, the intensity and pattern of staining with type VII collagen antibodies (LH7.2, NP185, etc.) are important. In the severe recessive form, type VII collagen immunofluorescence of the basement membrane is absent, while in the mild recessive form or the dominant form it is reduced or shows a normal distribution. To determine the site of blister separation, double staining with the LH7.2 antibody and a type IV collagen (lamina densa marker) antibody makes it possible to identify the level of separation.

COL7A1 molecular genetic testing is performed with an EB gene panel NGS or COL7A1 testing alone, and identification of pathogenic variants is the final step of confirmation. In the dominant form, a single heterozygous variant is identified; in the recessive form, pathogenic variants are identified on each of the two alleles. Detection of large deletions using MLPA is added as needed. Analysis of type VII collagen protein and mRNA through skin biopsy can be used as an additional means of confirmation.

10. Treatment

Treatment of epidermolysis bullosa dystrophica is based on supportive care, and gene therapy has recently been introduced into the clinic. Wound care is the most basic and core element of treatment, requiring intensive dressing care that can take several hours a day. Nonadhesive dressings (Mepilex Transfer, Mepitel One, etc.), absorbent pads, elastic bandages, etc. are combined with the goals of protecting blisters, preventing secondary infection, and minimizing pain. For pain management during dressing changes, opioid analgesics, NSAIDs, or nitrous oxide inhalation sedation are used.

Nutritional support is essential to overcome feeding difficulties due to esophageal stricture and oral pain. High-calorie concentrated nutrition, soft or liquid diets, and, when needed, enteral nutrition through a gastrostomy tube (PEG/PEJ) are provided. Esophageal dilation is performed for esophageal stricture, and repeated procedures are often needed. Procedures must be performed using aseptic dressing techniques, with care to avoid additional blister formation from instruments.

Skin cancer surveillance and treatment are central in severe RDEB. Wide surgical excision is the principle for SCC detected early, and for advanced or metastatic SCC, anticancer pharmacotherapy (cetuximab, immune checkpoint inhibitors, etc.) is tried.

As a historic milestone in gene therapy, beremagene geperpavec (Vyjuvek), approved by the FDA in 2023, is applied topically as a modified HSV-1 vector carrying COL7A1. Clinical trials confirmed that it reduces the frequency of blister formation and promotes wound healing. Cell therapies such as stem cell transplantation and bone marrow transplantation are also in clinical trials at some specialized centers. In addition, clinical trials of new drugs such as ropiranafraza (ropivarimab, etc.) are underway.

11. Prognosis

The prognosis of epidermolysis bullosa dystrophica differs greatly by subtype. The dominant form (DDEB) has a relatively good prognosis, and a normal or nearly normal lifespan is possible. However, lifelong blister formation, scarring, and the burden of continuous wound care reduce quality of life.

The prognosis of the severe recessive form (RDEB-generalized severe) is poor. In the past most patients died in childhood and adolescence, but with modern supportive care, survival into the 20s~30s has increased. However, cutaneous squamous cell carcinoma (SCC) has become the main cause of death in adulthood, and according to studies, the median age of survival of patients with severe RDEB is about 25~40 years. SCC follows an aggressive course, with a 5-year survival rate after diagnosis of less than 50%.

The causes of death are broadly sepsis (the main cause in the neonatal period to childhood), SCC (the main cause in adolescence to adulthood), and multiorgan failure due to malnutrition. With the recent introduction of gene therapy, improvement in long-term prognosis is expected, but at present a cure cannot be expected. Psychosocial support, palliative care, and a multidisciplinary team approach affect both quality of life and survival.

12. Prevention

The key to prevention of epidermolysis bullosa dystrophica is genetic counseling and prenatal/preimplantation diagnosis. Genetic specialist counseling and prenatal diagnosis are recommended for parents who have had an affected child (carriers of the recessive form), or for patients with the dominant form and their spouses (risk of dominant inheritance). The risk of an affected child is explained as 25% for the recessive form and 50% for the dominant form.

Prenatal diagnosis is performed by COL7A1 molecular genetic testing after CVS or amniocentesis, and identification of the causative familial mutation is a prerequisite. Preimplantation genetic diagnosis (PGD) can be offered as an alternative that selects out affected embryos without termination of pregnancy. In the dominant form, occurrence due to new mutations (de novo mutation) is also possible, so molecular genetic testing is recommended after clinical diagnosis even without a family history.

As secondary prevention in patients already diagnosed, minimizing skin blister formation is important. Education on avoiding trauma, wearing soft cotton clothing, using protective padding during social activities, and education on proper dressing techniques are provided. Regular dermatologic follow-up (at 6~12-month intervals) and patient self-monitoring education for early detection of skin cancer (SCC) are also important preventive measures. Minimizing UV exposure (sunscreen, protective clothing) may help prevent SCC.

13. References

  1. Fine JD, Bruckner-Tuderman L, Eady RA, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70(6):1103-1126. doi:10.1016/j.jaad.2014.01.903
  2. Christiano AM, Greenspan DS, Hoffman GG, et al. A missense mutation in type VII collagen in two affected siblings with recessive dystrophic epidermolysis bullosa. Nat Genet. 1993;4(1):62-66. doi:10.1038/ng0593-62
  3. Christiano AM, Ryynanen M, Uitto J. Dominant dystrophic epidermolysis bullosa: identification of a Gly-to-Ser substitution in the triple-helical domain of type VII collagen. Proc Natl Acad Sci USA. 1994;91(9):3549-3553. doi:10.1073/pnas.91.9.3549
  4. Kern JS, Grüninger G, Imsak R, et al. Forty-two novel COL7A1 mutations and the role of a frequent single nucleotide polymorphism in the MMP1 promoter in modulation of disease severity in a large European dystrophic epidermolysis bullosa cohort. Br J Dermatol. 2009;161(5):1089-1097. doi:10.1111/j.1365-2133.2009.09376.x
  5. Mellerio JE, Denyer JE, Greenhalgh A, Mee JB. Epidermolysis bullosa: a practical guide to management. Clin Exp Dermatol. 2007;32(4):371-378. doi:10.1111/j.1365-2230.2007.02411.x
  6. Murrell DF, ed. Blistering Diseases: Clinical Features, Pathogenesis, Treatment. Springer; 2015. ISBN 9783662451069.
  7. Gupta N, Koppikar S, Murrell DF. Squamous cell carcinoma in epidermolysis bullosa and current treatment options. Expert Rev Dermatol. 2011;6(6):577-592. doi:10.1586/edm.11.65
  8. Marinkovich MP, Tang JY. Gene Therapy for Epidermolysis Bullosa. J Invest Dermatol. 2019;139(6):1221-1226. doi:10.1016/j.jid.2018.11.036
  9. Siprashvili Z, Nguyen NT, Gorell ES, et al. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa. JAMA. 2016;316(17):1808-1817. doi:10.1001/jama.2016.15588
  10. Wally V, Klausegger A, Koller U, et al. 5' trans-splicing repair of the PLEC1 gene. J Invest Dermatol. 2008;128(3):568-574. doi:10.1038/sj.jid.5701152